DE68907430C5 - Cytotoxische Therapie. - Google Patents

Cytotoxische Therapie. Download PDF

Info

Publication number
DE68907430C5
DE68907430C5 DE68907430T DE68907430T DE68907430C5 DE 68907430 C5 DE68907430 C5 DE 68907430C5 DE 68907430 T DE68907430 T DE 68907430T DE 68907430 T DE68907430 T DE 68907430T DE 68907430 C5 DE68907430 C5 DE 68907430C5
Authority
DE
Germany
Prior art keywords
cytotoxic agent
disease
hematopoietic
treatment
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68907430T
Other languages
English (en)
Other versions
DE68907430D1 (en
DE68907430T2 (de
Inventor
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22636346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68907430(C5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of DE68907430D1 publication Critical patent/DE68907430D1/de
Application granted granted Critical
Publication of DE68907430T2 publication Critical patent/DE68907430T2/de
Publication of DE68907430C5 publication Critical patent/DE68907430C5/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Produkt, enthaltend:
a) ein cytotoxisches Mittel, in einer therapeutischen Menge, die zur Behandlung eines menschlichen Patienten, der an einer zur Behandlung mit einem cytotoxischen Mittel zugänglichen Krankheit leidet oder einer Gewebe- oder Organtransplantation unterzogen wird, wirksam ist, wobei dieses cytotoxische Mittel eine hämatopoetische oder myeloide Toxizität hervorruft, und
b) das Cytokin Thrombocyten-Wachstumsfaktor, in einer Menge, die im wesentlichen eine Prävention, Milderung oder Umkehr dieser hämatopoetischen oder myeloiden Toxizität bewirkt,
als kombiniertes Präparat zur Anwendung in einem Verfahren zur Therapie einer Krankheit oder Transplantatabstoßung,
worin das Cytokin vor, gleichzeitig mit oder im Anschluss an dieses cytotoxische Mittel verabreicht wird,
und worin die Krankheit Krebs oder eine Autoimmunerkrankung ist.

Description

  • Das europäische Patent 0 336 631 wurde durch Urteil des Bundespatentgerichts vom 08. März 2007 mit Wirkung für das Hoheitsgebiet der Bundesrepublik Deutschland dadurch teilweise für nichtig erklärt, dass die Patentansprüche folgende Fassung erhalten:

Claims (9)

  1. Produkt, enthaltend: a) ein cytotoxisches Mittel, in einer therapeutischen Menge, die zur Behandlung eines menschlichen Patienten, der an einer zur Behandlung mit einem cytotoxischen Mittel zugänglichen Krankheit leidet oder einer Gewebe- oder Organtransplantation unterzogen wird, wirksam ist, wobei dieses cytotoxische Mittel eine hämatopoetische oder myeloide Toxizität hervorruft, und b) das Cytokin Thrombocyten-Wachstumsfaktor, in einer Menge, die im wesentlichen eine Prävention, Milderung oder Umkehr dieser hämatopoetischen oder myeloiden Toxizität bewirkt, als kombiniertes Präparat zur Anwendung in einem Verfahren zur Therapie einer Krankheit oder Transplantatabstoßung, worin das Cytokin vor, gleichzeitig mit oder im Anschluss an dieses cytotoxische Mittel verabreicht wird, und worin die Krankheit Krebs oder eine Autoimmunerkrankung ist.
  2. Produkt gemäß Anspruch 1 zur Anwendung in einem Verfahren zur Therapie von Krebs.
  3. Produkt gemäß einem der vorangehenden Ansprüche, worin die hämatopoetische oder myeloide Toxizität in einer verminderten oder unterdrückten Erythrocytenzahl, Anzahl der weißen Blutkörperchen oder Thrombocytenzahl resultiert.
  4. Produkt gemäß einem der vorangehenden Ansprüche, wobei es sich bei dem cytotoxischen Mittel um ein Radioisotop, einen Arzneistoff oder ein Toxin handelt.
  5. Verwendung (a) eines cytotoxischen Mittels in einer therapeutischen Menge, die zur Behandlung eines menschlichen Patienten, der an einer zur Behandlung mit einem cytotoxischen Mittel zugänglichen Krankheit leidet oder einer Gewebe- oder Organtransplantation unterzogen wird, wirksam ist, wobei dieses cytotoxische Mittel eine hämotopoetische oder myeloide Toxizität hervorruft, und (b) des Cytokins Thrombocyten-Wachstumsfaktor, in einer Menge, die im wesentlichen eine Prävention, Milderung oder Umkehr dieser hämatopoetischen oder myeloiden Toxizität bewirkt, bei der Herstellung eines Mittels zur Verwendung in einem Verfahren zur Therapie einer Krankheit oder Transplantatabstoßung, wobei ein menschlicher Patient, der an einer der Behandlung mit einem cytotoxischen Mittel zugänglichen Krankheit leidet, mit dem cytotoxischen Mittel in einer therapeutischen Menge behandelt wird, die eine hämatopoetische oder myeloide Toxizität hervorruft, wobei bei diesem Verfahren eine Menge des Cytokins, die im Wesentlichen zur Prävention, Linderung oder Umkehr dieser hämatopoetischen oder myeloiden Toxizität ausreicht, dem Patienten vor, gleichzeitig mit oder im Anschluss an eine Exposition mit dem cytotoxischen Mittel verabreicht wird, und worin die Krankheit Krebs oder eine Autoimmunerkrankung ist.
  6. Verwendung gemäß Anspruch 5 zur Anwendung in einem Verfahren zur Therapie von Krebs.
  7. Verwendung gemäß einem der Ansprüche 5 oder 6, worin die hämatopoetische oder myeloide Toxizität in einer verminderten oder unterdrückten Erythrocytenzahl, Anzahl der weißen Blutkörperchen oder Thrombocytenzahl resultiert.
  8. Verwendung gemäß einem der Ansprüche 5 bis 7, wobei es sich bei dem cytotoxischen Mittel um ein Radioisotop, einen Arzneistoff oder ein Toxin handelt.
  9. Verwendung gemäß Anspruch 8, wobei es sich bei dem Arzneistoff um ein Krebsmittel handelt.
DE68907430T 1988-03-29 1989-03-29 Cytotoxische Therapie. Expired - Lifetime DE68907430C5 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17449088A 1988-03-29 1988-03-29
US174490 1988-03-29

Publications (3)

Publication Number Publication Date
DE68907430D1 DE68907430D1 (en) 1993-08-12
DE68907430T2 DE68907430T2 (de) 1993-11-04
DE68907430C5 true DE68907430C5 (de) 2007-11-29

Family

ID=22636346

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68907430T Expired - Lifetime DE68907430C5 (de) 1988-03-29 1989-03-29 Cytotoxische Therapie.

Country Status (15)

Country Link
US (1) US20070148088A1 (de)
EP (1) EP0336631B1 (de)
JP (1) JPH03504854A (de)
KR (1) KR0149002B1 (de)
AT (1) ATE91238T1 (de)
AU (1) AU634959B2 (de)
CA (1) CA1329119C (de)
DE (1) DE68907430C5 (de)
DK (1) DK235290D0 (de)
ES (1) ES2057112T3 (de)
FI (1) FI904786A0 (de)
IE (1) IE63011B1 (de)
IL (1) IL89794A (de)
WO (1) WO1989009061A1 (de)
ZA (1) ZA892303B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
CA1339415C (en) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection and treatment of infections with immunoconjugates
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DK0574395T3 (da) * 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
EP2445924B2 (de) 2009-06-25 2023-12-13 Amgen Inc. Vefahren zur aufreinigung von proteinen aus prokaryotischen zellen
CA2824719C (en) * 2011-01-19 2020-06-02 Cantargia Ab Anti-il1rap antibodies and their use for treating solid tumours
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4424200A (en) * 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4468457A (en) * 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4460459A (en) * 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4652440A (en) * 1984-05-03 1987-03-24 Paik Chang H Method of stably radiolabeling antibodies with technetium and rhenium
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4752925A (en) * 1984-11-13 1988-06-21 Hughes Aircraft Company Two-hop collocated satellite communications system
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
EP0215131B1 (de) * 1985-03-11 1992-06-17 Teijin Limited E87ag-antigen des pseudomonas aeruginosa, monoklonale antikörper dagegen und hybridom
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
JPH07100663B2 (ja) * 1985-12-23 1995-11-01 大日本製薬株式会社 インタ−ロイキン１を有効成分とする感染症予防・治療剤
JPH0618779B2 (ja) * 1986-01-22 1994-03-16 中外製薬株式会社 造血機能回復促進剤
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5328679A (en) * 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5128119A (en) * 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5180816A (en) * 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5095111A (en) * 1989-03-17 1992-03-10 The John Hopkins University Thiolactone bifunctional chelating agents for diagnostic and therapeutic products
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5005588A (en) * 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5399338A (en) * 1991-05-01 1995-03-21 University Of New Mexico Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
US5230886A (en) * 1992-03-18 1993-07-27 Trustees Of Boston University Tumor cell suppression
US5593666A (en) * 1994-08-16 1997-01-14 The University Of Tennessee Research Corp. Methods and compositions for treating thrombocytopenia
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects

Also Published As

Publication number Publication date
KR900700125A (ko) 1990-08-11
EP0336631B1 (de) 1993-07-07
DE68907430D1 (en) 1993-08-12
EP0336631A2 (de) 1989-10-11
KR0149002B1 (ko) 1998-10-15
US20070148088A1 (en) 2007-06-28
JPH03504854A (ja) 1991-10-24
IL89794A (en) 1995-03-30
ES2057112T3 (es) 1994-10-16
CA1329119C (en) 1994-05-03
WO1989009061A1 (en) 1989-10-05
IE890978L (en) 1989-09-29
DK235290A (da) 1990-09-28
DE68907430T2 (de) 1993-11-04
ATE91238T1 (de) 1993-07-15
IL89794A0 (en) 1989-09-28
EP0336631A3 (en) 1990-03-21
DK235290D0 (da) 1990-09-28
ZA892303B (en) 1989-12-27
AU634959B2 (en) 1993-03-11
AU3424989A (en) 1989-10-16
FI904786A0 (fi) 1990-09-28
IE63011B1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
DE68907430C5 (de) Cytotoxische Therapie.
DE69334101T2 (de) Verwendung von Blut mit erhöhter Stickoxidkonzentration zur Herstellung eines Medikaments
Rubin et al. Microcirculation of tumors part II: the supervascularized state of irradiated regressing tumors
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
Moress et al. Neuropathy in lymphoblastic leukemia treated with vincristine
DE69533873T2 (de) Krebstherapie mit lymphotoxin
DE2326600A1 (de) Arzneimittel zur behandlung von schocksymptomen
Chisholm et al. Factors influencing the distribution of antibacterial agents in interstitial tissue fluid: molecular size and protein binding
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
Shank et al. Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation
DE69835591T2 (de) Induktoren für immuntoleranz
Kyle Current therapy of multiple myeloma
Kolotas et al. Effect of recombinant human granulocyte colony stimulating factor (R-metHuG-CSF) as an adjunct to large-field radiotherapy: a phase I study
US3885030A (en) Medicine comprising lysine by-products
DE3707532C2 (de) Verwendung einer Kombination von Extr. Gingko biloba oder mindestens einem Gingkolid und Acetylsalicylsäure oder DL-Lysin-mono-acetylsalicylat oder Diflunisal zur Behandlung von Verbrennungen, Verbrühungen, Strahlenschäden und Erfrierungen
DE10133576A1 (de) Verwendung von physiologisch aktiven Oligopeptiden zur Stabilisierung des Immunsystems
EP0413792B1 (de) Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
DE3023396C2 (de) Arzneimittel zur intravenösen Krebstherapie
STURGIS Recent advances in treatment of hematologic disorders
Levine et al. Mitotic response to colchicine in human cancer.
DE19711795C2 (de) Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen
Beaumont Oral and Intravenous Clomipramine (Anafranil) in Depression: A Review of the Work of Dr. GH Collins
CA1155395A (en) Pharmaceutical composition having normolipidemic and platelet anti-binding activity
DE3234366A1 (de) Arzneimittel, insbesondere zur krebstherapie
RU2096048C1 (ru) Способ стимуляции костно-мозгового кроветворения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8310 Action for declaration of annulment
8328 Change in the person/name/address of the agent

Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG

8312 Partial invalidation
8394 Patent changed during the nullification procedure (changed patent specification reprinted)